前FDA疫苗主任Peter Marks在2025年10月加入Eli Lilly, Former FDA vaccine chief Peter Marks joins Eli Lilly in Oct 2025, sparking scrutiny over government-industry "revolving door."

曾在疫情期间领导疫苗批准并被卫生部长罗伯特·F·肯尼迪 (Robert F. Kennedy Jr.) 撤职的FDA前官员彼得·马克斯 (Peter Marks) 已加入伊利利利利 (Eli Lilly) 担任高级执行官,负责监督分子发现和传染病,自2025年10月起生效. Peter Marks, former FDA official who led vaccine approvals during the pandemic and was removed by Health Secretary Robert F. Kennedy Jr., has joined Eli Lilly as a senior executive overseeing molecule discovery and infectious diseases, effective October 2025. 美国食品药品监督管理局官员转移到制药公司, 这一趋势突出了政府和行业之间"旋转门"的日益严密审查. His appointment, part of a broader trend of FDA officials moving to pharmaceutical companies, highlights growing scrutiny over the "revolving door" between government and industry. Marks在监管科学和疫苗开发方面的专长有望加强Lilly在新兴疗法方面的研究工作。 Marks’ expertise in regulatory science and vaccine development is expected to bolster Lilly’s research efforts in emerging therapies.